Alvespimycin (17-DMAG) HCl

Catalog No.S1142 Synonyms: NSC 707545,BMS 826476 HCl,KOS 1022

For research use only.

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Alvespimycin (17-DMAG) HCl Chemical Structure

CAS No. 467214-21-7

Selleck's Alvespimycin (17-DMAG) HCl has been cited by 56 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Other HSP (HSP90) Products

Biological Activity

Description Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.
Features A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Targets
HSP90 [1]
(Cell-free assay)
62 nM
In vitro

17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62 nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well as induction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. [1] 17-DMAG in combination with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and Akt. [3] In contrast to 17-AAG which is only active for IKKβ in chronic lymphocytic leukemia (CLL) cells, 17-DMAG treatment effectively leads to depletion of the Hsp90 client protein, resulting in diminished NF-κB p50/p65 DNA binding, decreased NF-κB target gene transcription, and caspase-dependent apoptosis. By targeting the NF-κB family, 17-DMAG selectively mediates dose- and time-dependent cytotoxicity against CLL cells, but not normal T cells or NK cells important for immune surveillance. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKBr3 NVPZWmNtS3m2b4TvfIlkcXS7IHHzd4F6 NVHwWldOS3m2b4TvfIlkcXS7IHHnZYlve3RiU1vCdlMh[2WubIOsJGlEPTB;MD6wNlTPxE1w M4TXNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4MU[1N|U1Lz5zNkG2OVM2PDxxYU6=
SKBR3 NGDH[4RHfW6ldHnvckBie3OjeR?= M2XaO3VxemWpdXzheIlwdiCxZjDId5A4OCCrbjDTT2JTOyClZXzsd{whTUN3ME2wMlAxPM7:TT6= MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlYoRjF4OEW0NFY3RC:jPh?=
SKBR3 NFLPN49HfW6ldHnvckBie3OjeR?= NFvxcnZF\We{YXTheIlwdiCxZjDI[ZIzKGmwIGPLRnI{KGOnbHzzMEBGSzVyPUCuNFA5|ryPLh?= M1rsPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY3Lz5zNki1OFA3PjxxYU6=
SKOV3 NHzGTIRHfW6ldHnvckBie3OjeR?= MXHVdJJm\3WuYYTpc44hd2ZiSIPwO|AhcW5iU1vPWlMh[2WubIOsJGVEPTB;MD6wNVTPxE1w NYDVd3FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjZpPkG2PFU1ODZ4PD;hQi=>
SKOV3 NVTGR2F2TnWwY4Tpc44h[XO|YYm= MVnE[Ydz[WSjdHnvckBw\iCKZYKyJIlvKFONT2[zJINmdGy|LDDFR|UxRTBwMES2{txONg>? M2LZXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY3Lz5zNki1OFA3PjxxYU6=
AGS NVzBTIp[TnWwY4Tpc44h[XO|YYm= MknmNVYhcHK| MUTJcohq[mm2aX;uJI9nKEiLRkGgZYN1cX[jdHnvckBqdiCqdX3hckBCT1NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBpgXCxeHnhMYlv\HWlZXSgcJVkcW[ncnHz[UBmgHC{ZYPzbY9vKGGodHXyJFE3KGi{czDifUBz\XCxcoTldkBie3OjeTygTWM2OD1yLkCzOu69VS5? MnW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEO5OVAoRjF5NUizPVUxRC:jPh?=
Hep3B NG\HOZFHfW6ldHnvckBie3OjeR?= NIHQdY8yPiCqcoO= NUe5[lhtUW6qaXLpeIlwdiCxZjDITWYyKGGldHn2ZZRqd25iaX6gbJVu[W5iSHXwN2Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRibIXjbYZmemG|ZTDlfJBz\XO|aX;uJIFnfGW{IEG2JIhzeyCkeTDy[ZBwenSncjDhd5NigSxiSVO1NF0xNjB4Md88UU4> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6M{m1NEc,OTd3OEO5OVA9N2F-
AGS M1HqbmZ2dmO2aX;uJIF{e2G7 M3PuOFI1KGi{cx?= MnnsWoli[mmuaYT5JI9nKGi3bXHuJGFIWyClZXzsd{B2dmSncjDuc5Jud3irYzDjc45lcXSrb37zJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUdOwG0v MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6M{m1NEc,OTd3OEO5OVA9N2F-
NCI-H526 NHfqclFHfW6ldHnvckBie3OjeR?= NEO2fW8yKHWP MVOyOEBpenN? NE\pSGFDcW6maX7nJIFn\mmwaYT5JJRwKEiVUEmwJIlvKGi3bXHuJG5EUS2KNUK2JINmdGy|IHH0JFEhfU1iYX\0[ZIhOjRiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYm= NX7NZZJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFM2PDBpPkG3OlA{PTRyPD;hQi=>
NCI-H526 MlrpSpVv[3Srb36gZZN{[Xl? NXrYcG5YOSC3TR?= MXu5OkBpenN? M2S5XWlvcGmkaYTpc44hd2ZiSGPQPVAudWWmaXH0[YQheHKxbHnm[ZJifGmxbjDv[kBpfW2jbjDOR2kuUDV{NjDj[YxteyCjdDCxJJVOKGGodHXyJFk3KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7 M1nKVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCzOVQxLz5zN{[wN|U1ODxxYU6=
AGS M{TndGZ2dmO2aX;uJIF{e2G7 NYi3OVVCUW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNUBi[3SrdnH0bY9vKGmwIHj1cYFvKEGJUzDj[YxteyCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuNFA{Ps7:TT6= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN3OU[zNUc,OTh|NUm2N|E9N2F-
HeLa NI\DVnlHfW6ldHnvckBie3OjeR?= NGXuTYhKdmirYnn0bY9vKG:oIGTOSk1idHCqYT3pcoR2[2WmIF7GMYtieHCjQjDhZ5RqfmG2aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMtKEmFNUC9NE4yPc7:TT6= NF7GR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO1PVY{OSd-MUizOVk3OzF:L3G+
HeLa NWXMV5Y1S3m2b4TvfIlkcXS7IHHzd4F6 NVS3O4lmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;Mj6wOu69VS5? M4LoWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{W5OlMyLz5zOEO1PVY{OTxxYU6=
AGS MUXDfZRwfG:6aXPpeJkh[XO|YYm= Ml3BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRWdUKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPs7:TT6= MlrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|NUm2N|EoRjF6M{W5OlMyRC:jPh?=
A2058 NIfiPGNEgXSxdH;4bYNqfHliYYPzZZk> MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlA2QCClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEKx{txONg>? NFSyWGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEmyPVQ5Pid-MUi5Nlk1QDZ:L3G+
MDA-MB-231 M4XxZmZ2dmO2aX;uJIF{e2G7 NXLlWmMyUW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHjldlIh\GWpcnHkZZRqd25uIFnDOVA:OC5yMES1{txONg>? NFSzWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEmyPVQ5Pid-MUi5Nlk1QDZ:L3G+
MDA-MB-231 M3HFbWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXj6Z|NoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEW4{txONg>? Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7Mkm0PFYoRjF6OUK5OFg3RC:jPh?=
A2058 MnXHSpVv[3Srb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKEi|cEmwJIlvKGi3bXHuJGEzODV6IHPlcIx{NCCHQ{WwQVAvODB5Od88UU4> MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7Mkm0PFYoRjF6OUK5OFg3RC:jPh?=
MDA-MB-231 MYrGeY5kfGmxbjDhd5NigQ>? NVT0WoQyUW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IFHreEBl\We{YXTheIlwdixiSVO1NF0xNjBzN{dOwG0v MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{OUS4Okc,OTh7Mkm0PFY9N2F-
A2058 NX7EVplrTnWwY4Tpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKEi|cEmwJIlvKGi3bXHuJGEzODV6IHPlcIx{KGG|c3Xzd4VlKGG|IFHreEBl\We{YXTheIlwdixiSVO1NF0xNjB{NEROwG0v MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{OUS4Okc,OTh7Mkm0PFY9N2F-
HuH7 MXfBcpRqfmm{YXygZZN{[Xl? M33Cb|Mh\GG7cx?= MmTKRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGMhfmm{dYOg[4Vvd3S7cHWgNYIhS2:wMTDpcoZm[3SnZDDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KEeDUFTIJHJPSSCxcjCxPHMhelKQQTDs[ZZmdCCjZoTldkA{KGSjeYOgZpkheVKWLWDDVkBidmGueYPpd{whTUN3ME2wMlAxOTMQvF2u M{fVNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUO2NVkyLz5zOEmzOlE6OTxxYU6=
HuH7 Mn\iRY51cX[rcnHsJIF{e2G7 Mn71N{Bl[Xm| NVPIUnlkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMh\2Wwb4T5dIUhOWJiQ3;uNUBqdm[nY4Tl[EBqdiCqdX3hckBJfUh5IHPlcIx{KGG|c3Xzd4VlKGG|IFfBVGRJKFKQQTDvdkAyQFNicmLORUBt\X[nbDDh[pRmeiB|IHThfZMhe2WuZXP0[YQhf2m2aDC0NEBvVSCKQ2[tO|k3KGGwZDC4NFAhdk1iYn;j[ZBz\X[rcjDifUByWlRvUFPSJIFv[Wy7c3nzMEBGSzVyPUCuNFA{Oc7:TT6= NXjzNYpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5N|YyQTFpPkG4PVM3OTlzPD;hQi=>
SKBR3 MmnnSpVv[3Srb36gZZN{[Xl? NXnvXFR7SmmwZHnu[{Bi\m[rbnn0fUB1dyCKc4C5NEBqdiCqdX3hckBUU0KUMzDj[YxteyxiSVO1NF0xNjB{NN88UU4> NVnyRXM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNVc2PjJpPkG5NFE4PTZ{PD;hQi=>
Hep3B MoS0SpVv[3Srb36gZZN{[Xl? M{XOdlMxKG2rboO= M33GfmlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkHhcJBp[SCycn;0[YlvKGGlY4XteYxifGmxbjDpckBpfW2jbjDI[ZA{SiClZXzsd{B1emWjdHXkJIZweiB|MDDtbY5{KG2nYYP1doVlKGGodHXyJFEzKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNuIFnDOVA:OC5yNUey{txONg>? MnrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyN{KyNVQoRjF7MEeyNlE1RC:jPh?=
Hep3B MYPGeY5kfGmxbjDhd5NigQ>? M2S0UVE3KGi{cx?= M4jTNmlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKF[HR1[gdJJwfGWrbjDz[YNz\XSrb36gbY4hcHWvYX6gTIVxO0JiY3XscJMh[W[2ZYKgNVYhcHK|IHL5JGVNUVODLDDJR|UxRTBwMEe5Oe69VS5? NWLk[XVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwO|IzOTRpPkG5NFczOjF2PD;hQi=>
HCT116 MVHDfZRwfG:6aXPpeJkh[XO|YYm= NF;3cGI4OiCqcoO= NETGbYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFU4|ryPLh?= NHTx[I89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzNVg3PCd-MUmyN|E5PjR:L3G+
SKBR3 MmXJR5l1d3SxeHnjbZR6KGG|c3H5 M2nN[|czKGi{cx?= M2DzVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ|IHPlcIx{KGGodHXyJFczKGi{czygTWM2OD1yLkC1PO69VS5? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ|MUi2OEc,OTl{M{G4OlQ9N2F-
MCF7 NVzyT5Z5S3m2b4TvfIlkcXS7IHHzd4F6 M4OyNlczKGi{cx?= MkG2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVA:OC5yN{JOwG0v MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ|MUi2OEc,OTl{M{G4OlQ9N2F-
SKOV3 MVHDfZRwfG:6aXPpeJkh[XO|YYm= MUm3NkBpenN? M1PIfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KGGodHXyJFczKGi{czygTWM2OD1yLkGyNu69VS5? NVHOWpVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN|E5PjRpPkG5NlMyQDZ2PD;hQi=>
SKBR3 M2rXNGN6fG:2b4jpZ4l1gSCjc4PhfS=> NHTKUJQ4OiCqcoO= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVlGRMTDpcohq[mm2b4Kg[Ilkd3WvYYLvcEwhUUN3ME2wMlI{|ryPLh?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ|MUi2OEc,OTl{M{G4OlQ9N2F-
MCF7 MkDHR5l1d3SxeHnjbZR6KGG|c3H5 MVO3NkBpenN? NImzXYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDpckBxemW|ZX7j[UBw\iCQUV:xJIlvcGmkaYTvdkBlcWOxdX3hdo9tNCCLQ{WwQVAvQDZ{zszNMi=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ|MUi2OEc,OTl{M{G4OlQ9N2F-
NCI-H596 M4HVZ2N6fG:2b4jpZ4l1gSCjc4PhfS=> M3zrbVczKGi{cx?= NYfQOHI1S3m2b4TvfIlkcXS7IHHnZYlve3RiTmGwNU1l\W[rY3nlcpQhcHWvYX6gUmNKNUh3OU[gZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUGuNe69VS5? M2XhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkOxPFY1Lz5zOUKzNVg3PDxxYU6=
MDA468 NGiw[5BEgXSxdH;4bYNqfHliYYPzZZk> NFHh[WU4OiCqcoO= NIfQZ4FEgXSxdH;4bYNqfHliYXfhbY5{fCCQUUCxMYRm\mmlaXXueEBpfW2jbjDNSGE1PjhiY3XscJMh[W[2ZYKgO|IhcHK|LDDJR|UxRTFwNt88UU4> NWPqVmJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN|E5PjRpPkG5NlMyQDZ2PD;hQi=>
SKBR3 MYrDfZRwfG:6aXPpeJkh[XO|YYm= NHWxOnY4OiCqcoO= NYPnPZZNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uEUkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2pbH:gZZN{[XluIFnDOVA:OC5yMkVOwG0v M1Hte|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEC1OVI5Lz5zOUSwOVUzQDxxYU6=
A549 NVPpenZYS3m2b4TvfIlkcXS7IHHzd4F6 NX71NYZHPzJiaILz MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKt[4xwKGG|c3H5MEBKSzVyPUCuNFY5|ryPLh?= NV;lVok{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
SKOV3 MV3DfZRwfG:6aXPpeJkh[XO|YYm= M{HHNlczKGi{cx?= M{XDb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyudHn0[ZIu\2yxIHHzd4F6NCCLQ{WwQVAvOjMQvF2u NULWcFFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFU2OjhpPkG5OFA2PTJ6PD;hQi=>
MCF7 MmnhR5l1d3SxeHnjbZR6KGG|c3H5 NHnSOHo4OiCqcoO= NXnkcGNYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWeubzDhd5NigSxiSVO1NF0xNjJ|zszNMi=> Mmf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MEW1NlgoRjF7NEC1OVI5RC:jPh?=
CCRF-CEM MlXDR5l1d3SxeHnjbZR6KGG|c3H5 MV23NkBpenN? NHnOe2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LUm2JIFyfWWxdYOgc45mKHOxbIX0bY9vKGG|c3H5MEBKSzVyPUCuOVTPxE1w MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MEW1NlgoRjF7NEC1OVI5RC:jPh?=
CCRF-CEM NFjMPHhEgXSxdH;4bYNqfHliYYPzZZk> NFi2cpk4OiCqcoO= M3W2OWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBi[2yrdHH4[YwuemW|aYP0ZY51KEOFUl[tR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtPVYh[XG3ZX;1d{BwdmVic3;seZRqd25iYYPzZZktKEmFNUC9Nk42|ryPLh?= MkLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MEW1NlgoRjF7NEC1OVI5RC:jPh?=
Hep3B NFP2OHFHfW6ldHnvckBie3OjeR?= M17ySlMxKG2rboO= NXe5WlFRUW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNYFteGijIIDyc5RmcW5iYXPjeY12dGG2aX;uJIlvKGi3bXHuJGhmeDOEIHPlcIx{KHS{ZXH0[YQh\m:{IEOwJI1qdnNibXXhd5Vz\WRiYX\0[ZIhOTJiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OD1yLkC1O:69VS5? M3zqR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[5PFg4Lz5{MES2PVg5PzxxYU6=
Hep3B NXvOVo1bTnWwY4Tpc44h[XO|YYm= M2rjRVE3KGi{cx?= MXLJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBXTUeIIIDyc5RmcW5ic3XjdoV1cW:wIHnuJIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEG2JIhzeyCkeTDFUGlUSSxiSVO1NF0xNjB5Od88UU4> NXnybGZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0Olk5QDdpPkKwOFY6QDh5PD;hQi=>
HCT116 NI[2cIxEgXSxdH;4bYNqfHliYYPzZZk> NXTWXVY5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHL5JGFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUCuNFXPxE1w NFn3NFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[2NlU{PCd-MkC2OlI2OzR:L3G+
NCI-H1299 Ml\6SpVv[3Srb36gZZN{[Xl? MojBNlQhcHK| M1S4TWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOSOUCgbY4hcHWvYX6gUmNKNUhzMkm5JINmdGy|IHHzd4V{e2WmIHHzJGFsfCCmZXfyZYRifGmxbjDh[pRmeiB{NDDodpMh[nlibIXtbY5mgCCjc4PhfUwhUUN3ME2wMlHPxE1w MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2M{i1OFEoRjJzNEO4OVQyRC:jPh?=
LN229-Lux MXjGeY5kfGmxbjDhd5NigQ>? Mnj5Nk42KHSxIEGwJJVO MU[xJIhz MorNTY5pcWKrdHnvckBw\iCudXPp[oVz[XOnIHHjeIl3cXS7IHnuJIh2dWGwIFzONlI6NUy3eDDj[YxteyCjdDCyMlUhfG9iMUCgeW0hcW6ldXLheIVlKG[xcjCxJIhzKHWwZHXyJI5wem2xeHnhJIZwdGyxd3XkJIJ6KDJ2IHjyd{B2dmSncjDofZBwgGmjIHL5JJJmeG:{dHXyJIdmdmViYYPzZZk> M{XOO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{S2Nlc1Lz5{Mke0OlI4PDxxYU6=
MCF7 MlPWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3jGXVQ5KGi{cx?= NWTVR3RwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN7zszNMi=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6MkS3O{c,OjR3OEK0O|c9N2F-
HCT116 M4HKUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoXnOFghcHK| NEn2NGpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC55ON88UU4> MnT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEK0O|coRjJ2NUiyOFc4RC:jPh?=
SKBR3 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M4Lzc|Q5KGi{cx?= Ml\BRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS1LSN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4{PM7:TT6= M4n2R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUiyOFc4Lz5{NEW4NlQ4PzxxYU6=
A231 NEHP[IJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVr1VYZ{PDhiaILz MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{M{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjF5zszNMi=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{K2NUc,OjR5NkOyOlE9N2F-
MCF7 MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MWG0PEBpenN? MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjkQvF2u MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{K2NUc,OjR5NkOyOlE9N2F-
HCT116 NEnrXlRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4fEe|Q5KGi{cx?= NYDMOJBHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlIy|ryPLh?= MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkOyOlEoRjJ2N{[zNlYyRC:jPh?=
SKBR3 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mk\POFghcHK| NEHZUW9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLRnI{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mz6xNe69VS5? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4M{K2NUc,OjR5NkOyOlE9N2F-
NCI-H1299 NIqxeVdHfW6ldHnvckBie3OjeR?= NWnJWJdROTJiaILz NVvYb5p3WmWmdXP0bY9vKGmwIH;4fYdmdiClb37zeY1xfGmxbjDyZZRmKGmwIHj1cYFvKE6FST3INVI6QSClZXzsd{BqdmO3YnH0[YQh\m:{IEGyJIhzew>? NFf6U5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4N|kyPSd-MkWzPFM6OTV:L3G+
PC9 Mly4R5l1d3SxeHnjbZR6KGG|c3H5 MnroO|IhcHK| M{L0NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiJRj3pcoR2[2WmIHXycI91cW6rYj3y[ZNqe3SjboSgbJVu[W5iUFO5JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCx{txONg>? MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NES2PFkoRjJ4OES0Olg6RC:jPh?=
Ma1 MlLzR5l1d3SxeHnjbZR6KGG|c3H5 NX7tS5pPPzJiaILz MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBJT0ZvaX7keYNm\CCncnzveIlvcWJvcnXzbZN1[W62IHj1cYFvKE2jMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMd88UU4> NYmzTpFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4OFQ3QDlpPkK2PFQ1Pjh7PD;hQi=>
SKBR3 NYLyNFY5TnWwY4Tpc44h[XO|YYm= NVL5OHZ2UW6qaXLpeIlwdiCxZjDId5A6OCCrbjDoeY1idiCVS1LSN{Bk\WyuczygTWM2OD1yLkCyOO69VS5? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2NE[4PUc,OjZ6NES2PFk9N2F-
HeLa M1fjSGZ2dmO2aX;uJIF{e2G7 M4PUSVExKHWP M2rDR|YhcHK| NIXncZdKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGOqa{Gg[IVoemGmYYTpc44h[XRiMUCgeW0h[W[2ZYKgOkBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> NInoTW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEixOlQ1QSd-Mki4NVY1PDl:L3G+
HeLa M1rhUmZ2dmO2aX;uJIF{e2G7 MV[xNEB2VQ>? NHLtSII3KGi{cx?= NUjNdVdkUW6qaXLpeIlwdiCxZjDIV3A6OCCrbjDoeY1idiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCDa4Sg[IVoemGmYYTpc44h[XRiMUCgeW0h[W[2ZYKgOkBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> NGDZPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEixOlQ1QSd-Mki4NVY1PDl:L3G+
HeLa NXTmUHM1TnWwY4Tpc44h[XO|YYm= NVnEUFF3OTBidV2= M2HQ[VYhcHK| MmX5TY5pcWKrdHnvckBw\iCKU2C5NEBqdiCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBJW1B5MDDwdo91\WmwIHX4dJJme3Orb36gZZQhOTBidV2gZYZ1\XJiNjDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNkS0PUc,Ojh6MU[0OFk9N2F-
PC3 M4XrNGZ2dmO2aX;uJIF{e2G7 NVHBW|lyOTBidV2= NYrQVGJKPiCqcoO= MVPJcohq[mm2aX;uJI9nKEiVUEmwJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZ4hsOSCmZXfyZYRifGmxbjDheEAyOCC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m M2TNVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG2OFQ6Lz5{OEixOlQ1QTxxYU6=
PC3 Mo\nSpVv[3Srb36gZZN{[Xl? NFrVXGcyOCC3TR?= MknkOkBpenN? NFTmPIZKdmirYnn0bY9vKG:oIFjTVFkxKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhSWu2IHTl[5Ji\GG2aX;uJIF1KDFyIIXNJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S= NWf2S4pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NVY1PDlpPkK4PFE3PDR7PD;hQi=>
PC3 MlzCSpVv[3Srb36gZZN{[Xl? MVixNEB2VQ>? MlXQOkBpenN? M3T2dmlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hWEN|IHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBJW1B5MDDwdo91\WmwIHX4dJJme3Orb36gZZQhOTBidV2gZYZ1\XJiNjDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= MoTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MU[0OFkoRjJ6OEG2OFQ6RC:jPh?=
Assay
Methods Test Index PMID
Western blot HSP90 / HSP70 ; p-Akt / Survivin / MMP2 ; PARP / Cleaved caspase-3 / Cleaved caspase-8 / Cleaved caspase-9 / PUMA ; p-ALK / ALK / p-Akt / Akt / p-ERK / ERK ; α-Tax / α-IKKα / α-IKKβ/ α-NEMO / α-TBK1 / α-p65 / α-p50 28915605 26219569 24109220
Growth inhibition assay Cell proliferation 28915605
In vivo 17-DMAG treatment at 5 mg/kg or 25 mg/kg thrice per week significantly reduces tumor growth of TMK-1 xenografts, by significantly reducing vessel area and numbers of proliferating tumor cells in sections. [2] Consistent the inhibition of FAK signaling in vivo, 17-DMAG treatment at 25 mg/kg three times a week significantly suppresses tumor growth, and metastasis of ME180 and SiHa xenografts in mice. [4] Administration of 17-DMAG at 10 mg/kg for 16 days significantly decreases the white blood cell count and prolongs the survival in a TCL1-SCID transplant mouse model. [5]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence polarization (FP)-based competition binding assay:

    This assay utilizes a boron difluoride dipyrromethene (BODIPY) labeled geldanamycin analogue (BODIPY-AG) as a probe and measured fluorescence polarization upon binding of the probe to a protein. Native human Hsp90 protein (α + β isoforms) is isolated from HeLa cells. BODIPY-AG solution is freshly prepared in FP assay buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl2, 0.01% NP-40, 0.1 mg/mL fresh bovine γ-globulin (BGG), 1.0 mM fresh DTT, and protease inhibitor from stock solution in DMSO. Competition curves are obtained by mixing 10 μL each of a solution containing BODIPY-AG and Hsp90, and a serial dilution of 17-DMAG freshly prepared in FP assay buffer from stock solution in DMSO. Final concentrations are 10 nM BODIPY-AG, 40 or 60 nM Hsp90, varying concentration of 17-DMAG (0.10 nM-10 μM), and ≤0.25% DMSO in a 384-well microplate. After 3 hours incubation at 30 °C, fluorescence anisotropy (γEx = 485 nm, γEm = 535 nm) is measured on an EnVision 2100 multilabel plate reader. IC50 value of 17-DMAG is obtained from the competition curves.

Cell Research:[5]
  • Cell lines: Chronic lymphocytic leukemia (CLL)
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24, or 48 hours
  • Method: Cells are exposed to various concentrations of 17-DMAG for 24, or 48 hours. For the assessment of cytotoxicity, MTT reagent is then added, and plates are incubated for an additional 24 hours before spectrophotometric measurement. Apoptosis is determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI).
Animal Research:[5]
  • Animal Models: SCID mice engrafted with TCL1 leukemia cells
  • Dosages: 10 mg/kg
  • Administration: Intraperitoneal injection 5 times per week

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 653.21
Formula

C32H48N4O8•HCl

CAS No. 467214-21-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)C)OC)OC(=O)N)C)C)O)OC.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00780000 Terminated Drug: Alvespimycin Breast Cancer Bristol-Myers Squibb April 2008 Phase 2
NCT00248521 Unknown status Drug: alvespimycin hydrochloride Unspecified Adult Solid Tumor Protocol Specific Institute of Cancer Research United Kingdom|National Cancer Institute (NCI) October 2005 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl supplier | purchase Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl cost | Alvespimycin (17-DMAG) HCl manufacturer | order Alvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl distributor